Recent advances in the treatment of breast cancer

CWS Tong, M Wu, WCS Cho, KKW To - Frontiers in oncology, 2018 - frontiersin.org
Breast cancer (BC) is the most common malignancy in women. It is classified into a few
major molecular subtypes according to hormone and growth factor receptor expression …

Coumarins: old compounds with novel promising therapeutic perspectives

ME Riveiro, N De Kimpe, A Moglioni… - Current medicinal …, 2010 - ingentaconnect.com
Natural as well as synthetic coumarins have recently drawn much attention due to its broad
pharmacological activities. Many coumarins and their derivatives exert anti-coagulant, anti …

Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review

AJ Begam, S Jubie, MJ Nanjan - Bioorganic chemistry, 2017 - Elsevier
Estrogens display intriguing tissue selective action that is of great biomedical importance in
the development of optimal therapeutics for the prevention and treatment of breast cancer …

Steroid sulfatase inhibitors for estrogen-and androgen-dependent cancers

A Purohit, PA Foster - Journal of Endocrinology, 2012 - joe.bioscientifica.com
We have recently demonstrated the existence of a neuromodulatory regulation of prolactin
secretion by the opioid system showing a paradoxical opioid-induced prolactin suppression …

Steroid sulphatase and its inhibitors: past, present, and future

PA Foster - Molecules, 2021 - mdpi.com
Steroid sulphatase (STS), involved in the hydrolysis of steroid sulphates, plays an important
role in the formation of both active oestrogens and androgens. Since these steroids …

Sulfamic acid and its N-and O-substituted derivatives

W Spillane, JB Malaubier - Chemical reviews, 2014 - ACS Publications
In 1980 sulfamic acid and its N-substituted derivatives were reviewed in Chemical Reviews,
1 effectively updating an earlier 1940 review 2 also in Chemical Reviews. In 1991 the …

Molecular therapy of breast cancer: progress and future directions

SX Lin, J Chen, M Mazumdar, D Poirier… - Nature Reviews …, 2010 - nature.com
Breast cancer is a major cause of death in Western women, with a 10% lifetime risk of the
disease. Most breast cancers are estrogen-dependent. Molecular therapies for breast …

Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015)

IP Singh, P Shah - Expert Opinion on Therapeutic Patents, 2017 - Taylor & Francis
ABSTRACT Introduction: 1, 2, 3, 4-Tetrahydroisoquinoline (THIQ) is one of the 'privileged
scaffolds', commonly found in nature. Initially, this class of compounds was known for its …

Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis

JM Day, HJ Tutill, A Purohit… - Endocrine-related …, 2008 - erc.bioscientifica.com
Advanced medullary thyroid cancers (MTCs) are now being treated with drugs that inhibit
receptor tyrosine kinases, many of which involved in angiogenesis. Response rates vary …

Targeting stem cells in the realm of drug-resistant breast cancer

P Dey, M Rathod, A De - Breast Cancer: Targets and Therapy, 2019 - Taylor & Francis
Since its first documentation, breast cancer (BC) has been a conundrum that ails millions of
women every year. This cancer has been well studied by researchers all over the world …